JERUSALEM, Israel--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), Israel’s leading drug development company, today announced that it has signed a worldwide exclusive license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, one of the world’s leading technology transfer companies, and Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-4020, a novel peptide for the treatment of inflammatory diseases. Financial terms of the license were not disclosed.
